Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 228 participants.

Also called NCT06006689

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 228 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06006689
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06006689. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-15 (actual); primary completion 2025-04-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
Condition
Diabetic Kidney Disease
Intervention (Drug)
Qishen Yiqi Dripping Pills placebo 3 bags
Intervention (Drug)
Low dose Qishen Yiqi Dripping Pills 3 bags
Intervention (Drug)
High dose Qishen Yiqi Dripping Pills 3 bags
Lead sponsor
Tasly Pharmaceutical Group Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct06006689
Content hash
8ef43fc8d0810c568bc6e9a8dff439f7b7fcb43690ee4941c2a08718ebea8498